Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Australia OKs Paxlovid, Lagevrio & Nuvaxovid, New Sputnik Data Show ‘Strong Protection’ Against Omicron

Executive Summary

International regulators have broadened their discussions on the possible use of bivalent and multivalent vaccines, and the French presidency of the Council of the EU has called for “international solidarity” on vaccine provision.

You may also be interested in...



Coronavirus Notebook: UK Approves Novavax Vaccine, EMA Updates On Progress With Other Candidates

With the approval of Nuvaxovid, the UK and the EU now each have five COVID-19 vaccines at their disposal. Meanwhile, the European Medicines Agency has given an estimated timeline for the approval of candidate vaccines from Valneva and Sanofi Pasteur, and is looking at which therapeutics could be effective against the Omicron variant. Russia says its Sputnik V vaccine has now been granted full regulatory approval there.

EU Approves Paxlovid For COVID-19

The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.

EMA: Multiple COVID-19 Booster Programs ‘Not Sustainable’ In Long Term

Global regulators have been discussing how best to approach vaccination in the face of possible future coronavirus variants, and whether bivalent or multivalent vaccines could be the answer.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel